Results 21 to 30 of about 9,678,735 (383)

Statin usage, vascular diagnosis and vascular risk factors in Parkinson's disease [PDF]

, 2017
Background and aims: Vascular disease is a common comorbidity in Parkinson’s disease patients. Statins are potentially neuroprotective for Parkinson’s disease through non-vascular mechanisms.
Cheng, Kelvin K.W., Grosset, Donald G., Grosset, Katherine A., Swallow, Diane M.A.   +3 more
core   +1 more source

Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience

Frontiers in Neuroscience, 2021
The international Linked Clinical Trials (iLCT) program for Parkinson’s to date represents one of the most comprehensive drug repurposing programs focused on one disease.
Simon R. W. Stott, Richard K. Wyse, Patrik Brundin   +2 more
doaj   +1 more source

Physiotherapy intervention in Parkinson's disease: systematic review and meta-analysis [PDF]

, 2012
Objective To assess the effectiveness of physiotherapy compared with no intervention in patients with Parkinson’s disease. Design Systematic review and meta-analysis of randomised controlled trials.
Clarke, Carl E., Deane, Katherine H. O., Herd, Clare P., Ives, Natalie, Meek, Charmaine, Patel, Smitaa, Sackley, Catherine, Shah, Laila, Stowe, Rebecca, Tomlinson, Claire L., Wheatley, Keith   +10 more
core   +1 more source

Identifying Parkinson’s Patients: A Functional Gradient Boosting Approach [PDF]

, 2017
Parkinson’s, a progressive neural disorder, is difficult to identify due to the hidden nature of the symptoms associated. We present a machine learning approach that uses a definite set of features obtained from the Parkinson’s Progression Markers ...
Dhami, D. S., Natarajan, S., Page, D., Soni, Ameet   +3 more
core   +2 more sources

Palliative care for Parkinson’s disease: suggestions from a council of patient and carepartners

npj Parkinson's Disease, 2017
In 2015, the Parkinson’s Disease Foundation sponsored the first international meeting on Palliative Care and Parkinson’s disease and the Patient Centered Outcomes Research Institute funded the first comparative effectiveness trial of palliative care for ...
Kirk Hall, Malenna Sumrall, Gil Thelen, Benzi M. Kluger, on behalf of the 2015 Parkinson’s Disease Foundation sponsored “Palliative Care and Parkinson’s Disease” Patient Advisory Council   +4 more
doaj   +1 more source

How Cognition and Motivation “Freeze” the Motor Behavior in Parkinson’s Disease

Frontiers in Neuroscience, 2019
ObjectiveFreezing of gait (FoG) is a debilitating problem in patients with PD. The multifactorial pathogenesis of FoG remains poorly understood. We aimed to find which factors are most strongly associated with the occurrence of FoG.MethodsThree hundred ...
Paola Ortelli, Davide Ferrazzoli, Veronica Cian, Veronica Cian, Marianna Zarucchi, Grazia Palamara, Alessandro Giobbia, Giuseppe Frazzitta, Roberto Maestri, Margherita Canesi   +9 more
doaj   +1 more source

Elevated 5hmC levels characterize DNA of the cerebellum in Parkinson’s disease [PDF]

, 2017
5-methylcytosine and the oxidation product 5-hydroxymethylcytosine are two prominent epigenetic variants of the cytosine base in nuclear DNA of mammalian brains.
F Shephard, K Lunnon, KE Szulwach, M Mellen, RS Illingworth, S Horvath, S Shpyleva, S Starkstein, SF Field, T Wu, TF Kraus   +10 more
core   +2 more sources

Extended Timed Up and Go assessment as a clinical indicator of cognitive state in Parkinson\u27s disease [PDF]

, 2017
Objective: To evaluate a modified extended Timed Up and Go (extended-TUG) assessment against a panel of validated clinical assessments, as an indicator of Parkinson’s disease (PD) severity and cognitive impairment. Methods: Eighty-seven participants with
Anderton, R, Byrnes, M, Evans, T, Ghosh, S, Jefferson, A, Mastaglia, F, Power, B, Walters, S   +7 more
core   +2 more sources

Measuring anxiety in Lewy Body Disease – Which scale to choose?

Clinical Parkinsonism & Related Disorders, 2021
Background: Anxiety is among the most prevalent mood disorders in Lewy Body Disease (LBD) (i.e., Parkinson’s disease (PD), Dementia with Lewy bodies DLB), and those at-risk for developing LBD (e.g. isolated REM Sleep Behaviour Disorder (iRBD)).
Isabel Paniak, Simon J.G. Lewis, Kaylena A. Ehgoetz Martens   +2 more
doaj   +1 more source

Cognitive behavioral group therapy versus psychoeducational intervention in Parkinson's disease [PDF]

, 2018
Objective: The aim of the current study was to evaluate whether cognitive behavioral group therapy has a positive impact on psychiatric, and motor and non-motor symptoms in Parkinson’s disease (PD).
Berardelli, Isabella, Bloise, Maria Carmela, Bologna, Matteo, Conte, Antonella, Fabbrini, Giovanni, Lamis, Dorian A., Pasquini, Massimo, Pompili, Maurizio   +7 more
core   +2 more sources